CN112740037A - 糖化血红蛋白(％)测定方法 - Google Patents
糖化血红蛋白(％)测定方法 Download PDFInfo
- Publication number
- CN112740037A CN112740037A CN201980061828.9A CN201980061828A CN112740037A CN 112740037 A CN112740037 A CN 112740037A CN 201980061828 A CN201980061828 A CN 201980061828A CN 112740037 A CN112740037 A CN 112740037A
- Authority
- CN
- China
- Prior art keywords
- glycated hemoglobin
- monoclonal antibody
- hemoglobin
- sample
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000017011 Glycated Hemoglobin A Human genes 0.000 title claims abstract description 125
- 108091005995 glycated hemoglobin Proteins 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 103
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 71
- 238000005259 measurement Methods 0.000 claims abstract description 54
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 52
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 52
- 210000004369 blood Anatomy 0.000 claims abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 34
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims abstract description 24
- 238000003556 assay Methods 0.000 claims abstract description 19
- 238000000691 measurement method Methods 0.000 claims abstract description 11
- 239000004816 latex Substances 0.000 claims description 23
- 229920000126 latex Polymers 0.000 claims description 23
- 210000000601 blood cell Anatomy 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000004931 aggregating effect Effects 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 25
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 239000002245 particle Substances 0.000 description 21
- 210000004408 hybridoma Anatomy 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 239000007790 solid phase Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 230000004520 agglutination Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 108010013766 hemoglobin A(0) Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010085686 Hemoglobin C Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 102000023856 peptide binding proteins Human genes 0.000 description 3
- 108091008399 peptide binding proteins Proteins 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 2
- 101710178372 Prolyl endopeptidase Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JQXYBDVZAUEPDL-UHFFFAOYSA-N 2-methylidene-5-phenylpent-4-enoic acid Chemical compound OC(=O)C(=C)CC=CC1=CC=CC=C1 JQXYBDVZAUEPDL-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006097 fructosylation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000004375 physisorption Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-184017 | 2018-09-28 | ||
| JP2018184017 | 2018-09-28 | ||
| PCT/JP2019/038076 WO2020067396A1 (ja) | 2018-09-28 | 2019-09-27 | 糖化ヘモグロビン（％）の測定方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112740037A true CN112740037A (zh) | 2021-04-30 |
Family
ID=69950627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980061828.9A Pending CN112740037A (zh) | 2018-09-28 | 2019-09-27 | 糖化血红蛋白(％)测定方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210389306A1 (ko) |
| EP (1) | EP3859332B1 (ko) |
| JP (1) | JP7382071B2 (ko) |
| KR (1) | KR20210068048A (ko) |
| CN (1) | CN112740037A (ko) |
| SG (1) | SG11202103027UA (ko) |
| TW (1) | TW202020453A (ko) |
| WO (1) | WO2020067396A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4328318A1 (en) * | 2021-04-19 | 2024-02-28 | Osaka University | Method for characterizing molecule delivery particles |
| CN116046506B (zh) * | 2022-07-26 | 2023-11-10 | 南京立顶医疗科技有限公司 | 天然高纯度糖化血红蛋白HbA1c和血红蛋白HbA0的分离纯化方法 |
| CN115951072B (zh) * | 2022-12-06 | 2024-05-14 | 北京鸿宇泰生物科技有限公司 | 一种糖化血红蛋白-c肽联合检测试剂盒 |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582811A (en) * | 1983-02-02 | 1986-04-15 | Australian Monoclonal Development Pty. Ltd. | Method and diagnostic aid for detecting occult faecal blood |
| JPH06167495A (ja) * | 1992-07-14 | 1994-06-14 | S R L:Kk | 凝集イムノアッセイ法 |
| JPH0954088A (ja) * | 1995-08-11 | 1997-02-25 | Kdk Corp | 微量ヘモグロビン▲Ａ１ｃ▼測定用乾式試験具 |
| JPH1010127A (ja) * | 1996-06-25 | 1998-01-16 | Sekisui Chem Co Ltd | 凝集イムノアッセイ法 |
| WO2002088185A2 (en) * | 2001-04-26 | 2002-11-07 | Dakocytomation Denmark A/S | Pan-specific monoclonal antibody |
| CN1449495A (zh) * | 2000-08-29 | 2003-10-15 | 协和梅迪克斯株式会社 | 重现性良好的凝聚免疫分析法及其试剂 |
| KR20060023098A (ko) * | 2004-09-08 | 2006-03-13 | 주식회사 바이오포커스 | 당화헤모글로빈에 대해 특이성을 갖는 단일클론항체 개발및 정제방법 |
| US20100267048A1 (en) * | 2007-10-30 | 2010-10-21 | Panasonic Corporation | Method for measurement of hemoglobin and hemoglobin derivative, and measurement kit |
| US20110008908A1 (en) * | 2007-02-09 | 2011-01-13 | Medavinci Development B.V. | Apparatus and method for separating and analyzing blood |
| CN102246036A (zh) * | 2008-12-11 | 2011-11-16 | 积水医疗株式会社 | 含有糖化血红蛋白的试样的前处理方法 |
| CN104535756A (zh) * | 2008-07-04 | 2015-04-22 | 积水医疗株式会社 | 免疫学测定的灵敏度增强方法或避免血红蛋白影响的方法 |
| CN105137082A (zh) * | 2015-07-31 | 2015-12-09 | 柏荣诊断产品（上海）有限公司 | 一种双试剂糖化血红蛋白检测试剂盒 |
| JP2016031250A (ja) * | 2014-07-25 | 2016-03-07 | 株式会社堀場製作所 | 標的タンパク質の測定試薬および該試薬を用いた測定方法 |
| JP2017083440A (ja) * | 2015-10-23 | 2017-05-18 | 株式会社Ｌｓｉメディエンス | 免疫学的測定試薬、測定方法及び測定範囲の拡大方法 |
| WO2017139478A1 (en) * | 2016-02-09 | 2017-08-17 | Biomedomics, Inc. | Devices systems and methods for quantifying hemoglobin s concentration |
| CN107219372A (zh) * | 2017-05-31 | 2017-09-29 | 吉林省汇酉生物技术股份有限公司 | 一种糖化血红蛋白的检测试剂及方法 |
| CN108414767A (zh) * | 2018-01-31 | 2018-08-17 | 迈克生物股份有限公司 | 糖化血红蛋白测定试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339952C (en) | 1984-10-29 | 1998-07-14 | William J. Knowles | Immunoassays for denatured protein analytes, particularly hb alc, and monoclonal antibodies thereto |
| JP2596321B2 (ja) | 1992-06-16 | 1997-04-02 | 富士レビオ株式会社 | 糖化ヘモグロビンの測定方法 |
| JP2677753B2 (ja) * | 1993-07-22 | 1997-11-17 | 株式会社エスアールエル | 凝集イムノアッセイ法 |
| ES2268015T3 (es) | 2001-05-18 | 2007-03-16 | Srl, Inc. | Procedimiento de inmunoensayo. |
| JP2002365290A (ja) | 2001-06-06 | 2002-12-18 | Internatl Reagents Corp | 糖化ヘモグロビンの測定方法 |
| US8715942B2 (en) | 2007-11-20 | 2014-05-06 | Siemens Healthcare Diagnostics Inc. | Methods for the detection of glycated hemoglobin |
| US8603828B2 (en) | 2009-11-18 | 2013-12-10 | Bio-Rad Laboratories, Inc. | Multiplex immunoassays for hemoglobin, hemoglobin variants, and glycated forms |
| WO2014112318A1 (ja) | 2013-01-16 | 2014-07-24 | 富士レビオ株式会社 | 検体中のヘモグロビンA1cの免疫測定方法 |
-
2019
- 2019-09-27 KR KR1020217011325A patent/KR20210068048A/ko not_active Application Discontinuation
- 2019-09-27 SG SG11202103027UA patent/SG11202103027UA/en unknown
- 2019-09-27 JP JP2020549418A patent/JP7382071B2/ja active Active
- 2019-09-27 US US17/277,912 patent/US20210389306A1/en active Pending
- 2019-09-27 EP EP19865242.2A patent/EP3859332B1/en active Active
- 2019-09-27 TW TW108135133A patent/TW202020453A/zh unknown
- 2019-09-27 WO PCT/JP2019/038076 patent/WO2020067396A1/ja active Search and Examination
- 2019-09-27 CN CN201980061828.9A patent/CN112740037A/zh active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582811A (en) * | 1983-02-02 | 1986-04-15 | Australian Monoclonal Development Pty. Ltd. | Method and diagnostic aid for detecting occult faecal blood |
| JPH06167495A (ja) * | 1992-07-14 | 1994-06-14 | S R L:Kk | 凝集イムノアッセイ法 |
| JPH0954088A (ja) * | 1995-08-11 | 1997-02-25 | Kdk Corp | 微量ヘモグロビン▲Ａ１ｃ▼測定用乾式試験具 |
| JPH1010127A (ja) * | 1996-06-25 | 1998-01-16 | Sekisui Chem Co Ltd | 凝集イムノアッセイ法 |
| CN1449495A (zh) * | 2000-08-29 | 2003-10-15 | 协和梅迪克斯株式会社 | 重现性良好的凝聚免疫分析法及其试剂 |
| WO2002088185A2 (en) * | 2001-04-26 | 2002-11-07 | Dakocytomation Denmark A/S | Pan-specific monoclonal antibody |
| KR20060023098A (ko) * | 2004-09-08 | 2006-03-13 | 주식회사 바이오포커스 | 당화헤모글로빈에 대해 특이성을 갖는 단일클론항체 개발및 정제방법 |
| US20110008908A1 (en) * | 2007-02-09 | 2011-01-13 | Medavinci Development B.V. | Apparatus and method for separating and analyzing blood |
| US20100267048A1 (en) * | 2007-10-30 | 2010-10-21 | Panasonic Corporation | Method for measurement of hemoglobin and hemoglobin derivative, and measurement kit |
| CN104535756A (zh) * | 2008-07-04 | 2015-04-22 | 积水医疗株式会社 | 免疫学测定的灵敏度增强方法或避免血红蛋白影响的方法 |
| CN102246036A (zh) * | 2008-12-11 | 2011-11-16 | 积水医疗株式会社 | 含有糖化血红蛋白的试样的前处理方法 |
| JP2016031250A (ja) * | 2014-07-25 | 2016-03-07 | 株式会社堀場製作所 | 標的タンパク質の測定試薬および該試薬を用いた測定方法 |
| CN105137082A (zh) * | 2015-07-31 | 2015-12-09 | 柏荣诊断产品（上海）有限公司 | 一种双试剂糖化血红蛋白检测试剂盒 |
| JP2017083440A (ja) * | 2015-10-23 | 2017-05-18 | 株式会社Ｌｓｉメディエンス | 免疫学的測定試薬、測定方法及び測定範囲の拡大方法 |
| WO2017139478A1 (en) * | 2016-02-09 | 2017-08-17 | Biomedomics, Inc. | Devices systems and methods for quantifying hemoglobin s concentration |
| CN107219372A (zh) * | 2017-05-31 | 2017-09-29 | 吉林省汇酉生物技术股份有限公司 | 一种糖化血红蛋白的检测试剂及方法 |
| CN108414767A (zh) * | 2018-01-31 | 2018-08-17 | 迈克生物股份有限公司 | 糖化血红蛋白测定试剂盒 |
Non-Patent Citations (3)
| Title |
|---|
| HUANG-HAN CHEN 等: "Detection of Total and A1c-Glycosylated Hemoglobin in Human Whole Blood Using Sandwich Immunoassays on Polydimethylsiloxane-Based Antibody Microarrays", ANAL. CHEM., vol. 84, no. 20, 11 September 2012 (2012-09-11), pages 8635, XP002733322, DOI: 10.1021/ac301756d * |
| 齐为民 等: "单克隆抗体乳胶增强免疫法检测HbA1c的评价", 中国实验诊断学, vol. 13, no. 02, 31 December 2009 (2009-12-31), pages 215 - 217 * |
| 龚辉;康春香;田文洪;何英;曾丽吟;: "自身免疫性溶血性贫血红细胞相关抗体检测及临床分析", 内科急危重症杂志, no. 04, 15 August 2008 (2008-08-15), pages 201 - 202 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210068048A (ko) | 2021-06-08 |
| JPWO2020067396A1 (ja) | 2021-09-16 |
| EP3859332B1 (en) | 2023-08-23 |
| US20210389306A1 (en) | 2021-12-16 |
| TW202020453A (zh) | 2020-06-01 |
| EP3859332A1 (en) | 2021-08-04 |
| EP3859332A4 (en) | 2022-07-13 |
| SG11202103027UA (en) | 2021-04-29 |
| WO2020067396A1 (ja) | 2020-04-02 |
| JP7382071B2 (ja) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6172163B2 (ja) | 検体中のヘモグロビンＡ１ｃの免疫測定方法 | |
| KR102549704B1 (ko) | Pivka-ii의 측정 방법, 및 pivka-ii 면역측정 시약 또는 키트의 제조 방법 | |
| EP2322562A1 (en) | Monoclonal antibody, and immunoassay using same | |
| JP5199067B2 (ja) | 免疫凝集反応試薬キット及び抗原の測定方法 | |
| EP3859332B1 (en) | Glycated hemoglobin (%) assay method | |
| JPS61280571A (ja) | モノクロナ−ル抗体 | |
| WO2010067611A1 (ja) | ヘモグロビンβ鎖のＮ末端領域に対する抗体 | |
| JP2008175814A (ja) | 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット | |
| US9952230B2 (en) | Method of inhibiting nonspecific reaction in PIVKA-II assay reagent | |
| US20130052669A1 (en) | Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample | |
| EP2541252A1 (en) | Method of obtaining a binder to prepro-vasopressin or fragments thereof | |
| WO2023127881A1 (ja) | 検出方法及び検出試薬 | |
| JP4753366B2 (ja) | ％ｃｄｔの定量方法 | |
| US20220137071A1 (en) | Method and kit for measuring app669-711 | |
| WO2014177701A1 (en) | Process for diagnosing a human subject with diseases affecting the kidneys, or at risk of acquiring diseases affecting the kidneys | |
| CN114729935A (zh) | 使用免疫反应的分析物的测量方法和测量试剂 | |
| JP2005321411A (ja) | トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法 | |
| JP2003277398A (ja) | トランスフェリンを含む免疫複合体に対する抗体、抗体の製造方法、ハイブリドーマ及び免疫測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |